Use of novel casing in sucuk production: Antimicrobials incorporated into multilayer plastic film

In this study, effects of novel casing, antimicrobials (chitosan and AgZeo) incorporated into multilayer polyethylene casing, on chemical and microbial attributes of sucuks were followed through 3 days of fermentation and 12 days of storage after heat treatment. Microbial growth was reduced by chitosan incorporated casing. Aerobic plate count (APC) of 8.81 log CFU g–1 on the 3rd day of fermentation was reduced to 2.60 log CFU g–1 by the end of storage. APC and lactic acid bacteria (LAB) were decreased significantly (P<0.05) by antimicrobial casings. The lowest concentrations of histamine and tyramine were observed (P<0.05) in sucuks stuffed into chitosan incorporated casing. These results show that antimicrobial casing could be used in sucuk production to improve its safety and quality

Combined approach of density functional theory and quantum Monte Carlo method to electron correlation in dilute magnetic semiconductors

We present a realistic study for electronic and magnetic properties in dilute magnetic semiconductor (Ga,Mn)As. A multi-orbital Haldane-Anderson model parameterized by density-functional calculations is presented and solved with the Hirsch-Fye quantum Monte Carlo algorithm. Results well reproduce experimental results in the dilute limit. When the chemical potential is located between the top of the valence band and an impurity bound state, a long-range ferromagnetic correlations between the impurities, mediated by antiferromagnetic impurity-host couplings, are drastically developed. We observe an anisotropic character in local density of states at the impurity-bound-state energy, which is consistent with the STM measurements. The presented combined approach thus offers a firm starting point for realistic calculations of the various family of dilute magnetic semiconductors.Comment: 5 pages, 4 figure

Development and validation of an LC-MS/MS method for the quantification of KRASG12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study

Opnurasib (JDQ-443) is a highly potent and promising KRASG12C inhibitor that is currently under clinical investigation. Results of the ongoing clinical research demonstrated the acceptable safety profile and clinical activity of this drug candidate as a single agent for patients with NSCLC harboring KRASG12C mutations. In this early stage of development, a deeper insight into pharmacokinetic properties in both preclinical and clinical investigations of this drug is very important. Thus, a reliable quantification method is required. To date, no quantitative bioanalytical assay of opnurasib was publicly available. In this study we present a validated assay to quantify opnurasib in mouse plasma and eight mouse tissue-related matrices utilizing liquid chromatography-tandem mass spectrometry. Erlotinib was used as internal standard and acetonitrile was utilized to treat 10 µl of the sample with protein precipitation in a 96-well plate format. Separation and detection were achieved using a BEH C18 column under basic chromatographic conditions and a triple quadrupole mass spectrometer, respectively. We have fully validated this assay for mouse plasma and partially for eight mouse tissue-related matrices over the range of 2–2000 ng/ml. The accuracy and precision of the assay fulfilled international guidelines (EMA & U.S. FDA) over the validated range. The method was proven selective and sensitive to quantify opnurasib down to 2 ng/ml in all investigated matrices. The recoveries of both analyte and internal standard in mouse plasma were ∼100 % with no significant matrix effect in any of the matrices. Opnurasib in mouse plasma was stable up to 12 h at room temperature, and up to 8 h at room temperature in tissue homogenates (except for kidney up to 4 h). This presented method has been successfully applied to quantify opnurasib in preclinical samples from a mouse study and demonstrated its usability to support preclinical pharmacokinetic studies

ANKOS publisher application system and its impact on the e-resource evaluation process

The Publisher Application System (PAS) is a Web-based archiving and online evaluation system developed by the Database Evaluation Group (DEG), one of the working groups formed within the Anatolian University Libraries Consortium (ANKOS). The DEG was formed in 2008 to inquire and evaluate e-resources suited to the needs of the consortium; to follow up similar consortial activities worldwide as well as developments in connection with the scientific publishing industry; and to determine, implement, and improve pricing models in accordance with the prevailing economic, legal, and academic system. Development of the PAS was essential to ensure standardization and sustainability towards a more detailed and effective analysis of e-resources qualifying for evaluation by ANKOS. The PAS played an important part not only in establishing and defining the workflow of the DEG, but also in creating an archive of both the e-resources submitted to the consortium and the applicant publishers/agents submitting these resources. This article outlines the process that started with the foundation of the DEG through the formation of the PAS as well as the present setup of the system. It is also hoped that this case study will have a positive contribution to the processes being followed by the persons and the groups engaged in similar activities.pre-prin

ANKOS publisher application system and its impact on the e-resource evaluation process

The Publisher Application System (PAS) is a Web-based archiving and online evaluation system developed by the Database Evaluation Group (DEG), one of the working groups formed within the Anatolian University Libraries Consortium (ANKOS). The DEG was formed in 2008 to inquire and evaluate e-resources suited to the needs of the consortium; to follow up similar consortial activities worldwide as well as developments in connection with the scientific publishing industry; and to determine, implement, and improve pricing models in accordance with the prevailing economic, legal, and academic system. Development of the PAS was essential to ensure standardization and sustainability towards a more detailed and effective analysis of e-resources qualifying for evaluation by ANKOS. The PAS played an important part not only in establishing and defining the workflow of the DEG, but also in creating an archive of both the e-resources submitted to the consortium and the applicant publishers/agents submitting these resources. This article outlines the process that started with the foundation of the DEG through the formation of the PAS as well as the present setup of the system. It is also hoped that this case study will have a positive contribution to the processes being followed by the persons and the groups engaged in similar activities.pre-prin

A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: A focus on the incidence of graft-vs.-host disease and relapse

To detect the effect of the stem cell source, allogeneic peripheral blood stem cell transplantations (alloPBSCTs) performed between 1995 and 1997 from human leukocyte antigen (HLA)-identical siblings in 40 patients with acute and chronic hematological disorders were compared with a historical group of 40 patients with similar variables who had received allogeneic bone marrow transplants (alloBMTs) between 1993 and 1995. Patients in both groups were identical except that both the recipient and the donor ages were, on average, higher in the alloPBSCT group (26 vs. 36 [p = 0.005] and 27 vs. 32 [p = 0.024], respectively). Patients received similar therapy excluding posttransplant granulocyte colony-stimulating factor administration (97% in alloBMT vs. 12.5% in alloPBSCT). The median time to reach neutrophil counts &gt;0.5×109/L and platelet counts &gt;20×109/L was 13 and 14 days, respectively, in patients receiving alloPBSCTs compared with 19 and 27 days in patients receiving alloBMTs (p = 0.0014 and p = 0.0002). The alloPBSCT group required similar transfusions of red blood cells or platelets. The incidence of grade II-IV acute graft-vs.-host disease (aGVHD) was similar in both groups. However, chronic GVHD (cGVHD) of all grades developed in 78.1% of patients in the alloPBSCT group after a median follow-up period of 12.5 (range 0.5-34) months. In alloBMT recipients, cGVHD of all grades developed in 21.4% after a median follow-up period of 38 (range 0.5-62) months (p = 0.00001). Day 100 transplant-related mortality was also similar: 20% (8 of 40) in the alloBMT patients and 17.5% (7 of 40) in the alloPBSCT group. Although not statistically significant, a relatively higher relapse rate occurred in the alloBMT group (21.4 vs. 10.7%). The estimated disease-free survival in month 24 was 51.3% for alloBMT and 54.6% for alloPBSCT, and the estimated overall survival in month 24 was 56.1% for alloBMT and 64.6% for alloPBSCT. In conclusion, this retrospective comparison suggests that alloPBSCT from HLA-identical donors is associated with faster engraftment, fewer transfusions, and no greater incidence of aGVHD, but a high incidence of cGVHD

Comparison of plasma endothelin levels between osteoporotic, osteopenic and normal subjects

BACKGROUND: It has been demonstrated that endothelins (ET) have significant roles in bone remodeling, metabolism and physiopathology of several bone diseases. We aimed to investigate if there was any difference between the plasma ET levels of osteoporotic patients and normals. METHODS: 86 patients (70 women and 16 men) with a mean age of 62.6 (ranges: 51–90) years were included in this study. Patients were divided into groups of osteoporosis, osteopenia and normal regarding reported T scores of DEXA evaluation according to the suggestions of World Health Organization. According to these criteria 19, 43 and 24 were normal, osteopenic and osteoporotic respectively. Then total plasma level of ET was measured in all patients with monoclonal antibody based sandwich immunoassay (EIA) method. One-way analysis of variance test was used to compare endothelin values between normals, osteopenics and osteoporotics. RESULTS: Endothelin total plasma level in patients was a mean of 98.36 ± 63.96, 100.92 ± 47.2 and 99.56 ± 56.6 pg/ml in osteoporotic, osteopenic and normal groups respectively. The difference between groups was not significant (p > 0.05). CONCLUSION: No significant differences in plasma ET levels among three groups of study participants could be detected in this study